Heartseed, Inc. (JP:219A)
:219A
219A Stock Chart & Stats
¥1804.00
-¥95.00(-2.73%)
At close: 4:00 PM EST
¥1804.00
-¥95.00(-2.73%)
Day’s Range― - ―
52-Week Range¥1,343.00 - ¥4,385.00
Previous CloseN/A
Volume1.41M
Average Volume (3M)738.74K
Market Cap
¥44.37B
Enterprise Value¥37.46B
Total Cash (Recent Filing)¥7.34B
Total Debt (Recent Filing)¥890.00K
Price to Earnings (P/E)239.6
Beta1.19
Next Earnings
Jun 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,858,200
10 Day Avg. Volume469,170
30 Day Avg. Volume738,736
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)5.17
Price to Sales (P/S)12.93
P/FCF Ratio37.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-130.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageNear-zero debt and a large equity base provide durable financial flexibility. This reduces refinancing risk, supports sustained R&D and trial funding, and preserves optionality to pursue partnerships or M&A without immediate liquidity stress over the next 2–6 months.
Positive Operating And Free Cash FlowA substantive shift to positive operating and free cash flow indicates the business can internally finance activities and absorb shocks. If sustained, FCF parity with net income reduces dilution risk, enables reinvestment in trials, and strengthens long-term sustainability.
Partnerships/licensing-driven Revenue ModelA licensing and partnership model allows Heartseed to monetize technology without sole commercialization risk. Durable, non-dilutive revenue potential from partners and milestone streams can scale product reach and de-risk capital requirements as therapies progress toward market.
Bears Say
Prior Multi-year Losses And Cash BurnA history of multi-year losses and cash burn shows earnings volatility and execution risk; absent sustained operational improvements, the company could revert to funding dependence. This legacy increases uncertainty about repeatability of FY2025's turnaround.
Inconsistent Gross Profit ReportingInconsistent gross profit figures undermine confidence in margin comparability and long-term margin sustainability. This complicates forecasting of durable profitability and obscures whether FY2025 margins reflect recurring economics or one-off accounting/recognition effects.
Dependence On External Funding And Small ScaleReliance on external funding during clinical development is a structural vulnerability. It elevates dilution and execution risk if cash generation falters. Combined with a small team (39 employees), scalability and internal capacity to commercialize quickly are constrained.
Heartseed, Inc. News
219A FAQ
What was Heartseed, Inc.’s price range in the past 12 months?
Heartseed, Inc. lowest stock price was ¥1343.00 and its highest was ¥4385.00 in the past 12 months.
What is Heartseed, Inc.’s market cap?
Heartseed, Inc.’s market cap is ¥44.37B.
When is Heartseed, Inc.’s upcoming earnings report date?
Heartseed, Inc.’s upcoming earnings report date is Jun 11, 2026 which is in 62 days.
How were Heartseed, Inc.’s earnings last quarter?
Currently, no data Available
Is Heartseed, Inc. overvalued?
According to Wall Street analysts Heartseed, Inc.’s price is currently Overvalued.
Does Heartseed, Inc. pay dividends?
Heartseed, Inc. does not currently pay dividends.
What is Heartseed, Inc.’s EPS estimate?
Heartseed, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heartseed, Inc. have?
Heartseed, Inc. has 22,858,200 shares outstanding.
What happened to Heartseed, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Heartseed, Inc.?
Currently, no hedge funds are holding shares in JP:219A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heartseed, Inc.
Heartseed, Inc. engages in the provision of cardiac regenerative medicine. The company was founded by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa and Yutaro Kasai on November 30, 2015 and is headquartered in Tokyo, Japan.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Medical System Network Co., Ltd.
―
Shinnihonseiyaku Co., Ltd.
―
Chordia Therapeutics Inc.
―